Sogroya ISS Opinion: First-Mover EU Label Secured, But Payer Value Case Rests on Convenience Alone

CHMP Recommends Novo Nordisk's Sogroya for Idiopathic Short Stature

Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending once-weekly Sogroya (somapacitan) for children in Europe with idiopathic short stature (ISS) and persistent growth disturbance. If approved by the European Commission, Sogroya would be the first and only growth hormone treatment specifically for ISS in the EU, addressing a significant unmet need for up to 3% of children worldwide affected by this condition. This recommendation follows a previous positive CHMP opinion in May 2026 for Sogroya in children with short stature born Small for Gestational Age (SGA) and Noonan Syndrome (NS). The opinion is supported by data from the REAL8 Phase 3 clinical trial, which demonstrated Sogroya's non-inferiority to once-daily growth hormone treatment for mean annualised height velocity at Week 52.

• Regulatory Milestone for Idiopathic Short Stature: The CHMP's positive opinion for once-weekly Sogroya (somapacitan) marks a crucial step towards providing a dedicated treatment for children with idiopathic short stature (ISS) in Europe. This condition, affecting up to 3% of children globally, currently lacks approved growth hormone therapies in many regions, leading to significant psychosocial challenges for patients and their families.
• Clinical Efficacy Demonstrated in REAL8 Trial: The positive CHMP recommendation is underpinned by robust data from the Phase 3 REAL8 clinical trial. This study showed that once-weekly Sogroya was non-inferior to existing once-daily growth hormone treatments in achieving mean annualised height velocity at Week 52 in children with growth disorders, including ISS, Small for Gestational Age, and Noonan Syndrome.
• Expanding Therapeutic Reach in Growth Disorders: This latest recommendation for ISS builds upon Sogroya's growing portfolio of potential indications. The CHMP previously recommended Sogroya in May 2026 for short stature in children born Small for Gestational Age and with Noonan Syndrome. Furthermore, Sogroya is already authorised in the EU for growth hormone deficiency in adults (since March 2021) and in children aged 3 years and older (since July 2023), highlighting its versatility.

The Significant Unmet Needs in Idiopathic Short Stature

Current treatment approaches for idiopathic short stature (ISS) face a convergence of clinical, psychosocial, and economic challenges that complicate both decision-making and outcomes. While recombinant human growth hormone (rhGH) remains the primary intervention, its limitations span efficacy variability, safety concerns, adherence burdens, and unresolved questions around patient well-being.

• Modest and variable efficacy at the population level. Across three long-term randomised controlled trials conducted to adult height, the mean difference between GH-treated and untreated children with ISS was 0.77 ± 0.4 SDS (approximately 5.5 cm), with a mean adult height of -1.5 ± 0.3 SDS after therapy — meaning treated individuals remain relatively short compared with peers of normal height. Individual response is highly variable, and the predictors of response remain insufficiently characterised.

• Unresolved safety signals requiring ongoing vigilance. At dosages ≥ 0.3 mg/kg/week, a dose-dependent increase in mean fasting and stimulated insulin levels is observed. A continuing trend toward dose escalation to achieve greater height-promoting effects raises concerns about the possibility of delayed post-treatment effects of hyperinsulinemia and heightened GH and insulin-like growth factor I exposure on cancer risk, warranting caution and ongoing scrutiny of risks versus benefits. Additional adverse events — including scoliosis, slipped capital femoral epiphysis, intracranial hypertension, and pancreatitis — occur occasionally, though overall incidence remains low.

• Adherence challenges driven by daily injection burden. Missed injections are the only significant predictor of change in height SDS (β = -0.196, p = 0.048), making adherence a critical determinant of outcomes. Daily injections impose a significant burden on children and families, and adherence rates differ meaningfully across regimens — with short-acting rhGH showing a missed injection rate of 0.27% versus 0% for long-acting PEG-rhGH in one cohort — underscoring the clinical relevance of formulation choice.

• Weak and inconsistent evidence linking height gain to psychosocial well-being. The assumption that augmenting height directly leads to improved psychosocial well-being is not well supported by high-quality evidence. Recent studies indicate that psychosocial factors — including height-related beliefs, social support, and coping skills — play a more prominent role in promoting quality of life and self-esteem than height gain itself, challenging the prevailing clinical model.

• Cost-effectiveness concerns limiting broad justification for treatment. rhGH treatment for ISS has not been demonstrated to be cost-effective at standard willingness-to-pay thresholds. In combined GnRHa and rhGH therapy for girls with ISS and early puberty, each centimetre of height gained cost approximately €2,700 per patient — a figure that raises significant questions about resource allocation, particularly given the modest and variable height outcomes achieved.

• Gaps in long-term evidence and quality-of-life data. High-quality evidence from long-term randomised controlled trials continuing until adult height achievement is lacking, and quality-of-life assessments are rarely incorporated into cost-benefit analyses. Final height has not been shown to be associated with health-related quality of life in young adults treated with rhGH during childhood, further complicating the clinical rationale for treatment in this population.

REAL8 Trial Design and Key Efficacy for Sogroya

Two key trials evaluating recombinant human growth hormone (rhGH) in idiopathic short stature (ISS) provide complementary evidence on efficacy and safety across daily and long-acting formulations.

Sogroya's Role in the Evolving ISS Treatment Landscape

The treatment landscape for idiopathic short stature (ISS) has seen meaningful evolution, particularly with the emergence of long-acting growth hormone formulations as a clinically viable alternative to daily recombinant human GH (rhGH) therapy. A systematic review and meta-analysis encompassing 2,549 children demonstrated that once-weekly pegylated recombinant human GH (PEG-rhGH) achieves comparable short-term growth outcomes to daily rhGH at 6 and 12 months, with modest but statistically significant superiority in height SDS (MD = 0.10, 95% CI 0.01–0.19) and height velocity (MD = 0.74 cm/year, 95% CI 0.42–1.05) by 24 months. IGF-1 SDS did not differ significantly between the two modalities at 6 or 12 months. Safety analyses confirmed no increase in adverse or serious adverse events with PEG-rhGH compared to daily rhGH, with reactions characterized as generally mild and transient.

Dose optimization within long-acting regimens has emerged as a critical determinant of efficacy. In comparative dose analyses, 0.2 mg/kg/week PEG-rhGH produced substantially greater gains in height SDS and IGF-1 SDS than 0.1 mg/kg/week, with a time-dependent increase in the magnitude of effect — underscoring the importance of both dose selection and treatment duration in maximizing outcomes. Real-world data from a retrospective study of treatment-naïve children with isolated GHD further support the effectiveness of once-weekly somatrogon, though a significant increase in BMI z-score during the first 6 months in the weekly GH group was observed, raising questions about weight gain that warrant further investigation. Data from the KIGS cohort — the largest and longest-running international database of rhGH-treated children — established that in prepubertal patients with ISS, median first-year delta height-SDS was 0.55, with median near-adult height SDS gains of 1.37 for boys and 1.62 for girls, providing a robust real-world efficacy benchmark against which newer formulations continue to be assessed.

The convergence of these findings points to a treatment paradigm increasingly shaped by adherence considerations alongside efficacy. The burden of daily injections has long been recognized as a limiting factor in ISS management, and the demonstrated comparability — and potential long-term superiority — of weekly PEG-rhGH positions long-acting formulations as a strategically significant development for both clinical practice and commercial strategy. The knowledge base does not have sufficient information on this aspect regarding Sogroya-specific trial data within the ISS indication.

Sogroya Poised to Transform Pediatric ISS Treatment in Europe

The recent positive opinion from the European Medicines Agency's CHMP for once-weekly Sogroya (somapacitan) in children with idiopathic short stature (ISS) represents a pivotal moment for pediatric endocrinology. This recommendation, if followed by European Commission approval, would introduce the first and only growth hormone treatment specifically for ISS in the EU, addressing a significant unmet need for a condition that impacts a substantial number of children globally.

The core value proposition of Sogroya lies in its once-weekly administration. For families managing chronic conditions like short stature, the burden of daily injections can be immense, often leading to challenges with adherence. By offering a convenient, less frequent dosing schedule, Sogroya is poised to enhance patient and caregiver satisfaction, potentially improving treatment adherence and, consequently, optimizing long-term growth outcomes. This strategic move also solidifies Sogroya's position as a versatile long-acting growth hormone, building on its prior positive opinions for other non-GHD indications such as Small for Gestational Age and Noonan Syndrome.

However, as with any novel therapy, certain considerations remain important:

• Long-term Data: While the REAL8 trial demonstrated non-inferiority over 52 weeks, continued monitoring of Sogroya's long-term efficacy and safety in the ISS population will be crucial to fully understand its impact on final adult height and any potential long-term adverse events.

• Immunogenicity: Although studies have shown a favorable immunogenicity profile, ongoing surveillance for anti-drug antibodies and injection site reactions in a broader, real-world setting over extended treatment durations is warranted.

• IGF-I Management: Careful dose titration and monitoring of IGF-I levels will be essential to ensure optimal growth while maintaining these levels within a safe, normal range.

This development underscores a broader trend in pharmaceutical innovation towards patient-centric solutions that reduce treatment burden. Sogroya's potential entry into the ISS market could redefine the standard of care, offering a more convenient and effective option for children and families navigating the complexities of short stature.